Autor/-in: Matthias Giese

Matthias Giese has studied Molecular Biology and Biochemistry at the Saarland University/Germany.  He got a first PhD in Immunology in the German Cancer Research Center/ Heidelberg. In 1994, after Matthias Giese has joined the pharmaceutical industry some years ago, his team in Vienna/ Austria started the first European multicenter clinical trial with a personalized genetic engineered anti-melanoma vaccine.  Also Animal Health was interested in his expertise in modern vaccine technologies and so he changed the company and headed from now on a program on innovative vaccine approaches for the next years.  His sabbatical leave from the industry was a return back to the academic roots. At Leipzig University/ Germany Matthias Giese got a major PhD (venia legendi) in Molecular Virology. Currently he is working again for the human pharmaceutical industry and additionally he teaches graduate students as associate professor. His focus is on neoantigenes, therapeutical vaccines, and the interaction with immune checkpoint modifiers as combination therapy. Matthias Giese is author and editor of “Molecular Vaccines – From Prophylaxis to Therapy” and an enthusiastic mountain marathon runner.